Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myeloid, Chronic-Phase 7Recurrence 5Leukemia, Lymphocytic, Chronic, B-Cell 5Breast Neoplasms 5Multiple Myeloma 4Lymphoma, Large B-Cell, Diffuse 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia 4Carcinoma, Non-Small-Cell Lung 4Burkitt Lymphoma 4Waldenstrom Macroglobulinemia 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Extranodal NK-T-Cell 3Leukemia, Myeloid, Accelerated Phase 3Immunoblastic Lymphadenopathy 3Hodgkin Disease 3Blast Crisis 3Squamous Cell Carcinoma of Head and Neck 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Mycosis Fungoides 2

Interventions

Paclitaxel 20Carboplatin 16liposomal doxorubicin 10Bevacizumab 10Gemcitabine 8Topotecan 7Taxes 7Cisplatin 7pembrolizumab 6Doxorubicin 5Cyclophosphamide 5Nivolumab 4fludarabine 3Oxaliplatin 3Immunoglobulin G 3Hyperthermic Intraperitoneal Chemotherapy 3Disulfides 3Cytoreduction Surgical Procedures 3trebananib 2talazoparib 2rucaparib 2peginterferon alfa-2b 2olaparib 2fludarabine phosphate 2aldesleukin 2Surgical Procedures, Operative 2STA 9090 2Platinum 2Lenalidomide 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Fallopian Tube Neoplasms × Dasatinib × Clear all
NCT02059265 2023-08-01

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
35 enrolled 13 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡